The Powerhouse for Anti-infectives

Committed to making the difference

Read more

AiCuris is a pharmaceutical company specializing in the discovery, research and development of novel, resistance‐breaking antiviral and antibacterial agents for the treatment of serious and potentially life-threatening infectious diseases. Founded in 2006 as a spin‐out from Bayer Infection Research, AiCuris today manages an innovative pipeline of anti-infective agents with a team of internationally recognized scientists in Research and Development. We are one of the few European biotech companies which has brought a drug with “blockbuster” potential to the market (Prevymis® 2017/18).

Latest News


AiCuris AG Announces Appointment of Larry Edwards as Chief Executive Officer and Formation of U.S. Subsidiary

AiCuris welcomes Larry Edwards as new CEO. Mr. Edwards brings more than two decades of experience in executive and commercial leadership roles in the anti-infective space at both biotechnology and large pharmaceutical companies.

Read more


New publication on AiCuris´ Pritelivir Phase 3 drug candidate online

Pritelivir appears to be an effective and safe option for the management of acyclovir-r/r HSV infections in highly immunocompromised patients in an outpatient setting.

Read more


8th European Congress of Virology 2023, 4-7 May in Gdansk, Poland

Meet our Senior Manager Innovation & Alliance, Andreas Kühbacher, at Poster PP008 and discuss how to bridge the gap from fundamental virology to new antivirals.

Read more


AiCuris’ Licensing Partner MSD Demonstrates Efficacy in Phase 3 Study with PREVYMIS® for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation

In late breaking presentation at IDweek MSD reported positive findings from a phase 3 clinical trial that met the primary endpoint.

Read more


AiCuris´ AiCubator calls for innovative proposals to propel anti-infective drug development in the third round

AiCuris´ innovation accelerator AiCubator calls for innovative proposals to propel anti-infective drug development in the third round.

Read more


AiCuris nominates team of researchers from the Universitätsklinikum Erlangen as one of the winners of AiCubator Resident Status

AiCuris´s corporate innovation accelerator AiCubator has been strengthened by a novel collaboration with researchers from the Universitätsklinikum Erlangen.

Read more


AiCuris appoints experienced business leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer

“It is my pleasure to welcome Dr. Sabrina Kuttruff-Coqui as our new CFO”, said Dr. Stefan Oschmann, Chairman of the Board of AiCuris.

Read more


AiCuris befürwortet und unterstützt die Nationale Allianz für Pandemie-Therapeutika (NA-PATH)

NA-PATH ist eine Initiative des Helmholtz-Zentrums für Infektionsforschung (HZI) und des Deutschen Zentrums für Infektionsforschung (DZIF), die einen Sektor-übergreifenden Ansatz vorschlägt, um auf zukünftige Pandemien durch virale Erreger vorbereitet zu sein.

Read more

Research & Development

Our innovative Pipeline

Innovative therapies demand extraordinary means. With an international team of renowned scientists, proven competence in clinical development, and a global network of experts and reliable partners, we differentiate our pipeline by using an indication-driven, technology-agnostic approach.

Read more

Partnering & Collaborations

Expanding our Portfolio

AiCuris is constantly evaluating strategic partnerships and collaboration opportunities with biotech or pharmaceutical companies. In addition, we are always interested in new collaborations with innovative, science-driven organizations and academic institutions to develop the next resistance-breaking antibiotic or anti-infective.

Read more

If you or your company are interested in partnering with AiCuris, please contact us.